×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/23
09:14 am
mbrx
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]
Low
Report
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]
3/23
08:31 am
mbrx
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Medium
Report
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
3/19
08:10 pm
mbrx
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 [Yahoo! Finance]
Neutral
Report
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 [Yahoo! Finance]
3/19
08:36 am
mbrx
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Low
Report
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
3/17
09:14 am
mbrx
Moleculin to Present at 38th Annual ROTH Conference [Yahoo! Finance]
Medium
Report
Moleculin to Present at 38th Annual ROTH Conference [Yahoo! Finance]
3/17
09:05 am
mbrx
Moleculin to Present at 38th Annual ROTH Conference
Medium
Report
Moleculin to Present at 38th Annual ROTH Conference
3/11
09:14 am
mbrx
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study [Yahoo! Finance]
Low
Report
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study [Yahoo! Finance]
3/11
09:00 am
mbrx
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Medium
Report
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/23
08:30 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 23
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 23
3/19
08:45 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 19
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 19
3/19
08:35 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 19
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 19
3/18
04:07 pm
mbrx
Form 10-K Moleculin Biotech, Inc. For: Dec 31
Low
Report
Form 10-K Moleculin Biotech, Inc. For: Dec 31
3/9
03:58 pm
mbrx
Form DEF 14A Moleculin Biotech, Inc. For: Apr 15
Low
Report
Form DEF 14A Moleculin Biotech, Inc. For: Apr 15
2/27
02:10 pm
mbrx
Form PRE 14A Moleculin Biotech, Inc. For: Apr 15
Low
Report
Form PRE 14A Moleculin Biotech, Inc. For: Apr 15
2/20
08:50 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Feb 19
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Feb 19
2/18
04:32 pm
mbrx
Form 8-K Moleculin Biotech, Inc. For: Feb 18
High
Report
Form 8-K Moleculin Biotech, Inc. For: Feb 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
TOP News Decliners
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]
-50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: